Activation of antigen-exposed iMC-DCs at the %26quot;right place%26quot; and %26quot;right time%26quot; promotes potent anti-tumor immunity

作者：Spencer David M^*

来源：OncoImmunology, 2012, 1(3): 361-362.

DOI：10.4161/onci.18482

• dendritic cells
• MyD88
• CD40
• tumor immunotherapy
• inducible MyD88/CD40 (iMC)

To better control the %26quot;licensing%26quot; of pro-Th1 dendritic cells (DCs), Spencer and colleagues have developed a synthetic ligand-inducible chimeric receptor, iMyD88/CD40 (iMC), incorporating synergistic Toll-like receptor (TLR) and costimulatory signaling elements, permitting DC regulation in vivo within the context of an immunological synapse. This novel technology results in potent anti-cancer activity.

• 出版日期2012-6